Pyrazole-carrying synthetic cannabinoid receptor agonists that emerged to bypass China's 2021 ban showed minimal CB1/CB2 activation and even antagonistic properties, suggesting limited public health threat.
Read this if you work in forensic toxicology, drug policy, or want to understand how synthetic cannabinoid markets respond to legislation.
Mostly inactiveMost tested compounds showed essentially no CB1 or CB2 receptor activation
What the researchers found
Researchers tested 5F-3,5-AB-PFUPPYCA and five structural analogs using live cell assays. Most compounds were essentially inactive at both CB1 and CB2 receptors. Only three showed limited CB1 activation. All compounds exhibited antagonistic behavior at both receptors, resembling cannabinoid antagonists more than agonists. The position of the tail structure mattered — 5,3 regioisomers were more active than 3,5 analogs. Despite circumventing China's generic SCRA ban, these compounds are unlikely to produce the typical synthetic cannabinoid high.
Why it matters
The synthetic cannabinoid market rapidly evolves in response to legislation. This study shows that not all new compounds are equally dangerous — some structural modifications that evade legal definitions also strip away pharmacological activity.
The numbers in context
- 6 compounds tested (5F-3,5-AB-PFUPPYCA and 5 analogs)
- Most compounds essentially inactive at CB1 and CB2
- Only 3 of 6 showed limited CB1 activation potential
- All compounds showed antagonistic behavior at both receptors
- 5,3 regioisomers more active than 3,5 analogs
How the study worked
In vitro characterization using live cell beta-arrestin 2 recruitment assays to measure CB1 and CB2 receptor activation. Tested six structurally related pyrazole-carrying SCRAs for agonist and antagonist activity.
Who was studied
In vitro cell-based assays (no human subjects)
What this study cannot tell us
In vitro assays may not fully predict in vivo effects. Beta-arrestin recruitment is one signaling pathway; these compounds might activate other pathways not tested. The recreational drug market changes rapidly, and newer analogs could have different activity profiles.
How to read the evidence
In vitro pharmacological characterization. Strong methodology for receptor binding data but cannot predict full in vivo effects.
When this study was published
Published in 2023. Directly relevant to post-2021 synthetic cannabinoid market shifts.
The bigger picture
The cat-and-mouse game between drug designers and regulators sometimes produces compounds that are legally novel but pharmacologically weak. This research helps toxicologists and public health officials prioritize which emerging substances pose real threats.
Questions still open
- Could these compounds cause harm through their antagonistic properties rather than agonist effects?
- Will drug designers modify these scaffolds further to restore CB1 agonist activity?
- Are there other signaling pathways through which these compounds might be active?
Read the original research
In vitro characterization of the pyrazole-carrying synthetic cannabinoid receptor agonist 5F-3,5-AB-PFUPPYCA and its structural analogs.
Forensic science international, 343, 111565
Citation
Deventer, Marie H; Norman, Caitlyn; Reid, Robert; McKenzie, Craig; Nic Daéid, Niamh; Stove, Christophe P. (2023). In vitro characterization of the pyrazole-carrying synthetic cannabinoid receptor agonist 5F-3,5-AB-PFUPPYCA and its structural analogs.. Forensic science international, 343, 111565. https://doi.org/10.1016/j.forsciint.2023.111565